Carbyne Equity Partners (Hamburg, Germany) has announced the acquisition of SuanNutra (Fair Lawn, NJ), the nutraceutical ingredients business of Suanfarma, a portfolio company of ARCHIMED. The investment, marks Carbyne’s entry into the nutraceutical sector and aligns with its focus on building R&D-driven businesses alongside strong management teams. Further, the transaction supports Suanfarma’s renewed strategic focus on strengthening its position in the active pharmaceutical ingredients (API) market.

“SuanNutra is the company it is today because of the commitment, expertise and character of the people who have shaped it,” said Anthony Weston, CEO of SuanNutra. “Across the organization, colleagues have worked with dedication to strengthen our capabilities, refine our portfolio and build a culture that is both disciplined and ambitious. Their contribution has been central to the progress we have made and to the reputation SuanNutra now enjoys in our industry.

“As we look ahead, we are genuinely excited to be partnering with Carbyne,” Weston continued. “Their sector understanding, long-term approach and alignment with our values make them an excellent partner for the next phase of our journey. Together, we will continue to build on the strong foundations already in place, broaden our reach and develop the opportunities that lie ahead for our people, our customers and our partners.”

“SuanNutra is an impressive nutraceutical ingredients platform with meaningful opportunities ahead—whether through securing dedicated supply chains, broadening its portfolio of clinically validated ingredients or deepening its relevance among an already diverse customer base,” added Dr. Markus Petersen, managing partner at Carbyne. “We have great confidence in the management team and look forward to building the next chapter together.”

For more information, visit www.carbynepartners.de or https://suannutra.com.